1 Min Read
Jan 12 (Reuters) - Delcath Systems Inc :
* Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing
* Delcath Systems Inc - will announce interim results for cohort once data are fully mature
* Delcath Systems Inc - "original goal to obtain an efficacy signal for Phase 2 ICC cohort has been satisfied"
* Delcath Systems Inc - "PHP() therapy does, indeed, "demonstrate an efficacy signal in ICC and is worthy of full clinical investigation." Source text for Eikon: Further company coverage: